Product Information

CAS No.	1434635-54-7
Product Name	Firsocostat

Heavy Atom Count	40	Rotatable Bond Count	9
Atom Stereo Count	1	Bond Stereo Count	0
HBA	11	HBD	1
TPSA	135.020 Å²	Charge	0
Exact Mass	569.18319	Complexity	1644.44
pKa	4.610	XLogP	3.953

Studies related to this compound and its mechanism of action

Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.

Metabolites • Vol. 12, Issue 10 • 2022

PMID: 36295842 PMC: PMC9610518 DOI: 10.3390/metabo12100940

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Expert opinion on investigational drugs • Vol. 29, Issue 2 • 2020

PMID: 31984804 DOI: 10.1080/13543784.2020.1721169

Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.

PloS one • Vol. 15, Issue 1 • 2020

PMID: 31990961 PMC: PMC6986730 DOI: 10.1371/journal.pone.0228212

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Expert opinion on investigational drugs • Vol. 29, Issue 2 • 2020

PMID: 31519114 PMC: PMC7063378 DOI: 10.1080/13543784.2020.1668374

Firsocostat

CAS No.	1434635-54-7
MDL No.	N/A
MF	C₂₈H₃₁N₃O₈S
MW	569.60
InChI Key	ZZWWXIBKLBMSCS-FQEVSTJZSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1434635-54-7
Product Name	Firsocostat

Heavy Atom Count	40	Rotatable Bond Count	9
Atom Stereo Count	1	Bond Stereo Count	0
HBA	11	HBD	1
TPSA	135.020 Å²	Charge	0
Exact Mass	569.18319	Complexity	1644.44
pKa	4.610	XLogP	3.953

Firsocostat

Pricing & Availability

Product Information

Properties

Firsocostat

Pricing & Availability

Product Information

Properties

Documentation

Firsocostat

Pricing & Availability

Product Information

Properties

Related Articles

Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Similar Products

2-[1-[(2~{r})-2-(2-Methoxyphenyl)-2-(Oxan-4-Yloxy)ethyl]-5-Methyl-6-(1,3-Oxazol-2-Yl)-2,4-Bis(Oxidanylidene)thieno[2,3-D]pyrimidin-3-Yl]-2-Methyl-Propanamide

Firsocostat

Pricing & Availability

Product Information

Properties

Related Articles

Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Similar Products

2-[1-[(2~{r})-2-(2-Methoxyphenyl)-2-(Oxan-4-Yloxy)ethyl]-5-Methyl-6-(1,3-Oxazol-2-Yl)-2,4-Bis(Oxidanylidene)thieno[2,3-D]pyrimidin-3-Yl]-2-Methyl-Propanamide

Documentation